• Cardiology, Diabetes & Nephrology
    • Cardiology, Diabetes & Nephrology – London
    • Cardiology, Diabetes & Nephrology – Brazil
    • Cardiology, Diabetes & Nephrology – Canada
    • The Hatter Cardiovascular Institute Horizon Meetings
    • The 19th Malvern Diabetic Foot Conference
    • Previous Events
      • CDNATL 2022 – London
      • CDNATL 2019 – London
      • CDNATL 2019 – Brazil
      • CDNATL 2018
      • CDNATL 2017
      • CDNATL 2016
      • CDNATL 2015
      • CDNATL 2014
      • CDATL 2013
      • CDATL 2012
      • NATL 2012
      • CDATL 2011
      • CDATL 2010
      • NATL 2010
      • CATL 2009
      • NATL 2009
  • Cell Therapy
    • Cell Therapy at the Limits 2022
  • Oncology
    • Previous Events
      • Accelerating Cancer Immunotherapy 2017
      • OATL 2016
      • OATL 2015
      • OATL 2014
      • OATL 2012
      • OATL 2011
      • OATL 2010
      • UCL Frontiers of Oncology 2019
        • Haematology
        • Melanoma
        • Urology
        • Women’s Health
        • Lung Cancer
        • Gastrointestinal Oncology
  • Multiple Sclerosis
    • Multiple Sclerosis at the Limits 2022
    • Multiple Sclerosis Nurses at the Limits 2022
    • Previous events
      • Multiple Sclerosis at the Limits 2020
      • Multiple Sclerosis Nurses at the Limits 2020
      • Multiple Sclerosis Nurses at the Limits 2019
      • MSATL 2018: Introduction
      • MSATL 2017: Introduction
  • About
    • Academic Founders
    • Independence
    • The Lancet
    • Support & Sponsorship
    • Delegate Invitations
  • Supporters
  • Archive
    • CDNATL 2019 – London
    • CDNATL 2019 – Brazil
    • Multiple Sclerosis at the Limits 2018
    • Multiple Sclerosis at the Limits 2020
    • Multiple Sclerosis Nurses at the Limits 2020
    • Multiple Sclerosis Nurses at the Limits 2019
    • Hatter Horizon Series
      • Horizon GP Programme 2019
      • Hatter Horizon Series 2019
      • Hatter Horizon Series 2018
      • Hatter Horizon Series 2017
    • Cardiology, Diabetes & Nephrology at the Limits 2018
    • Accelerating Cancer Immunotherapy 2017
    • Oncology at the Limits 2017

Professor Ronald A. DePinho

Dr. Ronald A. DePinho, M.D., is President of the University of Texas MD Anderson Cancer Center in Houston. His research program has focused on the molecular underpinnings of cancer, aging and degenerative disorders and the translation of such knowledge into clinical advances.

Dr. DePinho’s independent scientific career began at the Albert Einstein College of Medicine, where he was the Feinberg Senior Faculty Scholar in Cancer Research. He then joined the Department of Medical Oncology at the Dana-Farber Cancer Institute and the Department of Medicine and Genetics at the Harvard Medical School. He was the founding Director of the Belfer Institute for Applied Cancer Science at the Dana-Farber Cancer Institute and a Professor of Medicine and Genetics at Harvard Medical School.

Dr. DePinho is a former member of the Board of Directors of the American Association for Cancer Research, and has served on numerous advisory boards in the public and private sectors, including co-chair of advisory boards for the NCI Mouse Models of Human Cancers Consortium and for The Cancer Genome Atlas Project. Dr. DePinho studied biology at Fordham University, where he graduated class salutatorian, and received his M.D. degree with distinction in microbiology and immunology from the Albert Einstein College of Medicine.

For his fundamental contributions to cancer and aging, he has received numerous honors and awards including the March of Dimes Basil O’Connor Scholar Award, the James S. McDonnell Foundation Scholar Award, the Cancer Research Institute Investigator Award, the Melini Award for Biomedical Excellence, the Irma T. Hirschl Career Scientist Award, the Kirsch Foundation Investigator Award, and the Richard P. and Claire W. Morse Scientific Award. He is the recipient of the 2002 American Society for Clinical Investigation Award, the 2003 AACR G.H.A. Clowes Memorial Award, the 2007 Biomedicum Helsinki Medal and the 2009 Albert Szent-Györgyi Prize. He is a member of the Institute of Medicine of the National Academies of Science. In 2010, Dr. DePinho was elected to membership in the American Academy of Arts and Sciences. In 2012, he was elected as a member of the National Academy of Sciences. He is a founder of a number of biopharmaceutical companies focused on cancer therapies and diagnostics.

« Professor David Collingridge
Professor Jeffrey Engelman »

The 19th Malvern Diabetic Foot Conference
Wednesday, 11 - Friday, 13 May 2022, Malvern, UK

Cell Therapy at the Limits 2022
Monday, 27 & Tuesday, 28 June 2022, London, UK

Multiple Sclerosis Nurses
at the Limits

Friday, 16 & Saturday, 17 September 2022, London, UK

Multiple Sclerosis at the Limits
Monday, 19 & Tuesday, 20 September 2022, London, UK

Cardiology, Diabetes & Nephrology at the Limits Japan
Saturday 15th & Sunday 16th October 2022, Tokyo, Japan

Cardiology, Diabetes & Nephrology at the Limits Canada
Q3 2022, Toronto, Canada

Cardiology, Diabetes & Nephrology at the Limits Brazil
April & October 2022, Brazil

The Hatter Cardiovascular Institute Horizon GP Meeting
Wednesday, 9 November 2022
London, UK

The Hatter Cardiovascular Institute Horizon Meeting
Wednesday, 23 November 2022, London, UK

Cardiology, Diabetes & Nephrology at the Limits 2023
London,UK

  • Contact
  • The Lancet
  • UCL
  • UCT
  • Brigham & Women’s Hospital
  • The University of Campinas
© 2022 At the Limits Ltd.
This site uses cookies More info